Logo for Pulmatrix Inc

Pulmatrix Investor Relations Material

Latest events

Logo for Pulmatrix Inc

M&A Announcement

Pulmatrix
Logo for Pulmatrix

Q4 2024

21 Mar, 2025
Logo for Pulmatrix

M&A Announcement

13 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Pulmatrix Inc

Access all reports
Pulmatrix Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases. The company utilizes its proprietary iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted) technology to formulate dry powder drugs for efficient delivery to the lungs. Pulmatrix's pipeline includes treatments for conditions such as chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and other respiratory disorders. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.